Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma

Cancer

Volumn 115, Issue 15, 2009, Pages 3468-3474

  Satoh, Takefumi ^a   Kimura, Masaki ^a   Matsumoto, Kazumasa ^a   Tabata, Ken Ichi ^a   Okusa, Hiroshi ^a   Bessho, Hideharu ^a   Iwamura, Masatsugu ^a   Ishiyama, Hiromichi ^a   Hayakawa, Kazushige ^a   Baba, Shiro ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Androgen deprivation therapy; Bisphosphonate; Bone mineral density; Prostate carcinoma

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; GONADORELIN AGONIST; ZOLEDRONIC ACID;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMUR NECK; HUMAN; JAW OSTEONECROSIS; LUMBAR SPINE; MALE; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; UREMIA;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; DIPHOSPHONATES; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PILOT PROJECTS; PROSTATIC NEOPLASMS;

EID: 68149164800     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24404     Document Type: Article

References (21)

1. Kawakami J, Cowan JE, Elkin EP, et al. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer. 2006;106:1708-1714.
2. Shahinian VB, Kuo YF, Freeman JL, et al. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005;103:1615-1624.
3. Akaza H. Trends in primary androgen depletion therapy for patients with localized and locally advanced prostate cancer: Japanese perspective [review]. Cancer Sci. 2006;97:243-247.
4. Berruti A, Dogliotti L, Terrone C, et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol. 2002;167:2361-2367; discussion 2367.
5. Greenspan SL, Coates P, Sereika SM, et al. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab. 2005;90:6410-6417.
6. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154-164.
7. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol. 2002;168:1005-1007.
8. Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003;169:2008-2012.
9. Kimura M, Satoh T, Okazaki M, et al. Clinical significance of risedronate for patients with prostate cancer receiving androgen deprivation therapy. Jpn J Urol. 2008;99:22-28.
10. Ryan CW, Huo D, Demers LM, et al. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol. 2006;176:972-978; discussion 978.
11. Israeli RS, Rosenberg SJ, Saltzstein DR, et al. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer. 2007;5:271-277.
12. Michaelson MD, Kaufman DS, Lee H, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol. 2007;25:1038-1042.
13. Orimo H. Diagnostic criteria of osteoporosis. The Japanese Society for Bone and Mineral Research Consensus Statement 2000. Osteoporosis Jpn. 2001;9:9-14.
14. Baim S, Wilson CR, Lewiecki EM, et al. Precision assessment and radiation safety for dual-energy X-ray absorptiometry: position paper of the International Society for Clinical Densitometry. J Clin Densitom. 2005;8:371-378.
15. Roach M III, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and externalbeam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008;26:585-591.
16. D'Amico AV, Denham JW, Bolla M, et al. Short- vs longterm androgen suppression plus external beam radiation therapy and survival in men of advanced age with nodenegative high-risk adenocarcinoma of the prostate. Cancer. 2007;109:2004-2010.
17. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360:103-106.
18. Alibhai SM, Gogov S, Allibhai Z. Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol. 2006;60:201-215.
19. Groot MT, Boeken Kruger CG, Pelger RC, Uyl-de Groot CA. Costs of prostate cancer, metastatic to the bone, in the Netherlands. Eur Urol. 2003;43:226-232.
20. Greenspan SL, Nelson JB, Trump DL, et al. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med. 2007;146:416-424.
21. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458-1468.